Linkage of cell division cycle 42 with clinical features, treatment response and survival in adult Philadelphia chromosome negative acute lymphoblastic leukemia

References

• Yi M, Zhou L, Li A, et al. Global burden and trend of acute lymphoblastic leukemia from 1990 to 2017. Aging. 2020;12(22):22869–22891. doi: 10.18632/aging.103982.
   PubMedGoogle Scholar
• Chang JH, Poppe MM, Hua CH, et al. Acute lymphoblastic leukemia. Pediatr Blood Cancer. 2021;68(Suppl. 2):e28371.
   PubMedGoogle Scholar
• Davis K, Sheikh T, Aggarwal N. Emerging molecular subtypes and therapies in acute lymphoblastic leukemia. Semin Diagn Pathol. 2023;40(3):202–215. doi: 10.1053/j.semdp.2023.04.003.
   PubMed Web of Science ®Google Scholar
• Iacobucci I, Mullighan CG. Genetic basis of acute lymphoblastic leukemia. J Clin Oncol. 2017;35(9):975–983. doi: 10.1200/JCO.2016.70.7836.
   PubMed Web of Science ®Google Scholar
• Foà R, Chiaretti S. Philadelphia chromosome—positive acute lymphoblastic leukemia. N Engl J Med. 2022;386(25):2399–2411. doi: 10.1056/NEJMra2113347.
   PubMed Web of Science ®Google Scholar
• Brown PA, Shah B, Advani A, et al. Acute lymphoblastic leukemia, version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021;19(9):1079–1109. doi: 10.6004/jnccn.2021.0042.
   PubMedGoogle Scholar
• Rafei H, Kantarjian HM, Jabbour EJ. Recent advances in the treatment of acute lymphoblastic leukemia. Leuk Lymphoma. 2019;60(11):2606–2621. doi: 10.1080/10428194.2019.1605071.
   PubMed Web of Science ®Google Scholar
• DeAngelo DJ, Jabbour E, Advani A. Recent advances in managing acute lymphoblastic leukemia. Am Soc Clin Oncol Educ Book. 2020;40:330–342. doi: 10.1200/EDBK_280175.
   PubMedGoogle Scholar
• Locatelli F, Maschan A, Boissel N, et al. Pediatric patients with acute lymphoblastic leukemia treated with blinatumomab in a real-world setting: results from the NEUF study. Pediatr Blood Cancer. 2022;69(4):e29562.
   PubMed Web of Science ®Google Scholar
• Boissel N, Chiaretti S, Papayannidis C, et al. Real-world use of blinatumomab in adult patients with B-cell acute lymphoblastic leukemia in clinical practice: results from the NEUF study. Blood Cancer J. 2023;13(1):2. doi: 10.1038/s41408-022-00766-7.
   PubMed Web of Science ®Google Scholar
• Crosas-Molist E, Samain R, Kohlhammer L, et al. Rho GTPase signaling in cancer progression and dissemination. Physiol Rev. 2022;102(1):455–510. doi: 10.1152/physrev.00045.2020.
   PubMed Web of Science ®Google Scholar
• Maldonado MDM, Dharmawardhane S. Targeting Rac and Cdc42 GTPases in cancer. Cancer Res. 2018;78(12):3101–3111. doi: 10.1158/0008-5472.CAN-18-0619.
   PubMed Web of Science ®Google Scholar
• Mizukawa B, O'Brien E, Moreira DC, et al. The cell polarity ­determinant CDC42 controls division symmetry to block ­leukemia cell differentiation. Blood. 2017;130(11):1336–1346. doi: 10.1182/blood-2016-12-758458.
   PubMed Web of Science ®Google Scholar
• Wurzer H, Filali L, Hoffmann C, et al. Intrinsic resistance of chronic lymphocytic leukemia cells to NK cell-mediated lysis can be overcome in vitro by pharmacological inhibition of Cdc42-induced actin cytoskeleton remodeling. Front Immunol. 2021;12:619069. (doi: 10.3389/fimmu.2021.619069.
   PubMed Web of Science ®Google Scholar
• Yan J, Wan D. Dysregulation of circulating CDC42 and its correlation with demographic characteristics, comorbidities, tumor features, chemotherapeutic regimen and survival profile in non-small-cell lung cancer patients. J Clin Lab Anal. 2022;36(2):e24140. doi: 10.1002/jcla.24140.
   PubMed Web of Science ®Google Scholar
• Gao S, Xue J, Wu X, et al. The relation of blood cell division control protein 42 level with disease risk, comorbidity, tumor features/markers, and prognosis in colorectal cancer patients. J Clin Lab Anal. 2022;36(7):e24572.
   PubMed Web of Science ®Google Scholar
• Yang D, Zhang Y, Cheng Y, et al. High expression of cell division cycle 42 promotes pancreatic cancer growth and predicts poor outcome of pancreatic cancer patients. Dig Dis Sci. 2017;62(4):958–967. doi: 10.1007/s10620-017-4451-z.
   PubMed Web of Science ®Google Scholar
• Ramakrishnan A, Datta I, Panja S, et al. Tissue-specific biological aging predicts progression in prostate cancer and acute myeloid leukemia. Front Oncol. 2023;13:1222168. doi: 10.3389/fonc.2023.1222168.
   PubMed Web of Science ®Google Scholar
• Wang W, Zou H, Chen N, et al. Knockdown of CLAUDIN-6 inhibited apoptosis and induced proliferation of bovine cumulus cells. Int J Mol Sci. 2022;23(21):13222.
   PubMed Web of Science ®Google Scholar
• Hematology Oncology Committee, Chinese Anti- Cancer Association; Leukemia & Lymphoma Group, Chinese Society of Hematology, Chinese Medical Association. Chinese guidelines for diagnosis and treatment of acute lymphoblastic leukemia (2016). Zhonghua Xue Ye Xue Za Zhi. 2016;37(10):837–845.
   PubMedGoogle Scholar
• Wang J, Rao Q, Wang M, et al. Overexpression of Rac1 in leukemia patients and its role in leukemia cell migration and growth. Biochem Biophys Res Commun. 2009;386(4):769–774. doi: 10.1016/j.bbrc.2009.06.125.
   PubMed Web of Science ®Google Scholar
• Jain N, Lamb AV, O'Brien S, et al. Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype. Blood. 2016;127(15):1863–1869. doi: 10.1182/blood-2015-08-661702.
   PubMed Web of Science ®Google Scholar
• Roberts KG, Mullighan CG. The biology of B-Progenitor acute lymphoblastic leukemia. Cold Spring Harb Perspect Med. 2020;10(7):a034835. doi: 10.1101/cshperspect.a034835.
   PubMed Web of Science ®Google Scholar
• Petrides PE, Dittmann KH. How do normal and leukemic white blood cells egress from the bone marrow? Morphological facts and biochemical riddles. Blut. 1990;61(1):3–13. doi: 10.1007/BF01739426.
   PubMedGoogle Scholar
• Wu A, Jiang X. p21-Activated kinases as promising therapeutic targets in hematological malignancies. Leukemia. 2022;36(2):315–326. doi: 10.1038/s41375-021-01451-7.
   PubMed Web of Science ®Google Scholar
• Yao D, Li C, Rajoka MSR, et al. P21-activated kinase 1: emerging biological functions and potential therapeutic targets in cancer. Theranostics. 2020;10(21):9741–9766. doi: 10.7150/thno.46913.
   PubMed Web of Science ®Google Scholar
• Hou Y, Zi J, Ge Z. High expression of RhoF predicts worse overall survival: a potential therapeutic target for non-M3 acute myeloid leukemia. J Cancer. 2021;12(18):5530–5542. doi: 10.7150/jca.52648.
   PubMed Web of Science ®Google Scholar
• Iwasaki T, Katsumi A, Kiyoi H, et al. Prognostic implication and biological roles of RhoH in acute myeloid leukaemia. Eur J Haematol. 2008;81(6):454–460. doi: 10.1111/j.1600-0609.2008.01132.x.
   PubMed Web of Science ®Google Scholar
• Mulloy JC, Cancelas JA, Filippi MD, et al. Rho GTPases in hematopoiesis and hemopathies. Blood. 2010;115(5):936–947. doi: 10.1182/blood-2009-09-198127.
   PubMed Web of Science ®Google Scholar
• Del Principe MI, Maurillo L, Buccisano F, et al. Central nervous system involvement in adult acute lymphoblastic leukemia: diagnostic tools, prophylaxis, and therapy. Mediterr J Hematol Infect Dis. 2014;6(1):e2014075. doi: 10.4084/MJHID.2014.075.
   PubMedGoogle Scholar